University of Leicester Selects Sygnature Chemical Services To Support Wellcome Trust-Funded Pneumococcal Diseases Project

Published: May 21, 2010

Nottingham and Leicester, UK – 20th May 2010 – Sygnature Chemical Services Ltd., a leading UK-based provider of premium discovery chemistry services to the global pharmaceutical industry, today announced that it has been selected by the University of Leicester to support a Wellcome Trust Seeding Drug Discovery Initiative (SDDI)-funded research programme. Under the terms of the agreement, Sygnature will provide synthetic, medicinal and computational chemistry services to help Leicester identify new treatments for the serious neurological handicaps associated with invasive pneumococcal diseases.

“Sygnature has been chosen by the University of Leicester to provide discovery chemistry support to this important research project,” said Dr Simon Hirst, Sygnature’s CEO. “For the past 18 months, Sygnature has been supplying medicinal chemistry resource and expertise into a Wellcome Trust SDDI-funded project for another UK university. This has advanced well, and Sygnature’s selection for a second Wellcome Trust-funded project is a testament to the successful application of our know-how and expertise in medicinal and computational chemistry. I am confident that Sygnature will be able to make a significant contribution to the University of Leicester’s pneumococcal diseases programme."

About Sygnature Chemical Services Ltd.

Sygnature Chemical Services, founded in 2004, is a leading Nottingham, UK-based provider of premium discovery chemistry services (medicinal chemistry, synthetic chemistry, array/focused library and computational chemistry). The company delivers high value and quality to its clients by applying in-house scientific expertise and ‘state-of-the-art’ technologies to the discovery of novel drug candidates. Sygnature’s team of 34 industry-experienced chemists (75% with PhDs) undertakes key elements of the drug discovery process, such as hit identification, hit-to-lead and lead optimisation, to afford novel compounds in a time-efficient and cost-effective manner. We work closely with our clients’ scientists to accelerate their drug candidates into development and thereby increase the value of their R&D discovery programmes. Over the past five years, Sygnature has established an enviable reputation and excellent track record of success with an international client base. For more information, visit

Back to news